Sumary of Probiotics Do Not Aid Prevention of Ventilator-Assisted Pneumonia:
- The probiotic Lactobacillus rhamnosus GG produced no significant difference compared to placebo for critically-ill patients in terms of the prevention of ventilator-assisted pneumonia (VAP), according to a paper published in JAMA.
- Investigators from Canada enrolled 2650 adult patients across 44 intensive care units who required mechanical ventilation for at least 72 hours in order to determine the effect of L rhamnosus GG on preventing VAP and/or additional infections.
- Between October 2013 and March 2019, patients were randomized to receive enteral L rhamnosus GG (1 × 1010 colony-forming units) or placebo twice daily in the ICU, the study authors wrote.
- Probiotics are being theorized as a potential strategy for treatment or prevention of various infectious, inflammatory, or autoimmune conditions, the study authors explained.
- They noted that some literature has suggested probiotics can reduce infection rates by 20 percent and VAP specifically by 25 to 30 percent.
- All were receiving mechanical ventilation at baseline (for a median of 7 days), while a further 61 percent were receiving inotropes or vasopressors, and 8 percent were receiving kidney replacement therapy, the investigators noted.
- For the group that received probiotics, 21.9 percent developed VAP compared to 21.3 percent of patients in the placebo group, the investigators determined.
- Secondary outcomes were also similar between the intervention and placebo groups, including development of C difficile infection (2.4 percent in the L rhamnosus GG group vs.